Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE versus SATRIC.
ATOVAQUONE vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain complex III (cytochrome bc1 complex) in parasites, thereby disrupting pyrimidine synthesis and energy metabolism.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
750 mg oral suspension twice daily for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia; 1500 mg oral suspension once daily for prophylaxis.
No standard dosing information available for SATRIC.
None Documented
None Documented
Clinical Note
moderateAtovaquone + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Atovaquone."
Clinical Note
moderateAtovaquone + Artemether
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
Clinical Note
moderateAtovaquone + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."
Clinical Note
moderateAtovaquone + Dapsone
Terminal elimination half-life is approximately 2-3 days (67 hours) in adults, prolonged in renal or hepatic impairment.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily fecal (>94%) as unchanged drug; renal excretion is minimal (<1%).
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category A/B
Category C
Antiprotozoal
Antiprotozoal, Antibiotic
"The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone."